Publication | Closed Access

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

MedicineCancer ManagementGynecologyRecurrent Ovarian CancerNiraparib Versus PlaceboCancer TreatmentOncologyGynecology OncologyPhase 3Ovarian Cancer